tizanidine has been researched along with Palsy in 7 studies
tizanidine: RN given refers to parent cpd; structure
tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficiency and duration of action of a single oral dose (8 mg) of tizanidine in patients with spinal cord injuries were determined by studying its antispastic, cardiovascular and sedative effects along with its pharmacokinetic profile in five tetraplegic and five paraplegic patients." | 3.67 | Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. ( Baker, H; Desai, P; el Masri, W; Frankel, HL; Luckitt, J; Mathias, CJ, 1989) |
| " The study consisted of 4 parts: I, double-blind cross-over trial at maximal dosage 10 mg/day in 13 patients; II, open trial at maximal dosage 32 mg/day in 10 patients; III, long-term medication at dosage 32 mg/day for 6-15 months in 4 patients; IV, single dose (12 mg) administration in 3 patients." | 2.65 | Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis. ( Gransberg, L; Knutsson, E; Mårtensson, A, 1982) |
| "Selective role of spasticity was estimated in clinical pattern of motor disorders in groups of the patients with different disorders of muscular tonus with the same degree of paresis." | 1.30 | [Disorders of muscle tonus and their treatment with sirdalud in patients in the early recovery period of ischemic stroke]. ( Beliakov, VV; Burd, GS; Gekht, AB; Iaish, F; Selikhova, MV, 1998) |
| "Twelve spastic patients received single oral doses of a new anti-spastic drug DS103-282 (Sandoz) 6 mg, baclofen 20 mg, and placebo on three separate days." | 1.26 | Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity. ( Hassan, N; McLellan, DL, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (71.43) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Knutsson, E | 2 |
| Mårtensson, A | 1 |
| Gransberg, L | 1 |
| Hassan, N | 1 |
| McLellan, DL | 1 |
| Gekht, AB | 1 |
| Burd, GS | 1 |
| Selikhova, MV | 1 |
| Iaish, F | 1 |
| Beliakov, VV | 1 |
| Rösche, J | 1 |
| Gerstenbrand, F | 1 |
| Lorincz, A | 1 |
| Ludin, HP | 1 |
| Ringwald, E | 1 |
| Mathias, CJ | 1 |
| Luckitt, J | 1 |
| Desai, P | 1 |
| Baker, H | 1 |
| el Masri, W | 1 |
| Frankel, HL | 1 |
1 trial available for tizanidine and Palsy
| Article | Year |
|---|---|
Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis.
Topics: Adult; Aged; Clinical Trials as Topic; Clonidine; Dose-Response Relationship, Drug; Double-Blind Met | 1982 |
6 other studies available for tizanidine and Palsy
| Article | Year |
|---|---|
Analysis of gait and isokinetic movements for evaluation of antispastic drugs or physical therapies.
Topics: Cerebral Palsy; Clonidine; Electromyography; Gait; Humans; Motor Neurons; Muscle Contraction; Muscle | 1983 |
Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.
Topics: Adolescent; Adult; Aged; Baclofen; Clonidine; Double-Blind Method; Electromyography; Female; Hemiple | 1980 |
[Disorders of muscle tonus and their treatment with sirdalud in patients in the early recovery period of ischemic stroke].
Topics: Adult; Aged; Brain Ischemia; Clonidine; Female; H-Reflex; Humans; Male; Middle Aged; Muscle Relaxant | 1998 |
Treatment of spasticity.
Topics: Acetates; Amines; Aminopyridines; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Clonidine; Cy | 2002 |
[Long-term treatment with an imidazoline derivative (DS 103--282) (author's transl)].
Topics: Arm; Clonidine; Female; Humans; Leg; Male; Multiple Sclerosis; Muscle Spasticity; Paralysis; Urinati | 1979 |
Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury.
Topics: Administration, Oral; Adult; Blood Pressure; Clonidine; Drug Evaluation; Heart Rate; Humans; Male; M | 1989 |